The report “Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).
The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468
Objectives of the Study
# To define, measure, and describe the global human liver model market by type and region
# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW
Animal models accounted for the largest share of the market in 2017
The human liver models market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. In 2017, the animal models segment accounted for the largest share of the global market. The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data.
Preclinical research also helps in securing a clear definition of targets. Moreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars and preclinical services is likely to increase. The rising demand for preclinical services, in turn is expected to drive the demand for animal models.
Target Audience:
# Pharmaceutical and biotechnology companies
# Chemical companies
# Cosmetic product manufacturers, suppliers, and distributors
# Healthcare providers and diagnostic laboratories
# Manufacturers of 3D Cell Culture products
# Food & beverage manufacturers
# Contract research organizations (CROs)
# Research institutes/universities
# Research and consulting firms
# Venture capitalists
Request Sample Pages@
North America held the largest share of the market in 2017
In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.
The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.
The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).
No comments:
Post a Comment